Geron to Announce First Quarter 2024 Financial Results on May 2, 2024Business Wire • about 23 hours ago
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its first quarter 2024 financial results and business highlights before the...
Share to Feed
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 243,000 shares of Geron...
Latest Ratings for GERN
DateFirmActionFromTo Nov 2021BairdInitiates Coverage OnOutperform Aug 2020HC Wainwright & Co.MaintainsBuy Aug 2020StifelInitiates Coverage OnBuy
View More Analyst...
China Universal Asset Management Co. Ltd. lifted its position in shares of Geron Co. (NASDAQ:GERN - Free Report) by 367.9% in the 4th quarter, according to the company in its most recent Form 13F...
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Gerons Chairman and Chief Executive Officer, is scheduled to present at...
Geron Co. (NASDAQ:GERN - Get Free Report) was the target of a significant growth in short interest during the month of March. As of March 15th, there was short interest totalling 50,950,000 shares, a...
Investors in Geron Corp. (GERN) saw new options become available today, for the August 16th expiration...
Investors in Geron Corp. (GERN) saw new options become available today, for the May 3rd expiration...
Geron Co. (NASDAQ:GERN Get Free Report) shares saw unusually-strong trading volume on Monday after The Goldman Sachs Group raised their price target on the stock from $4.00 to $5.00. The...
Geron (NASDAQ:GERN Free Report) had its price objective raised by The Goldman Sachs Group from $4.00 to $5.00 in a research report released on Friday, Benzinga reports. The brokerage...